Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease

This study has been terminated.
(Celgene unable to continue funds.)
Sponsor:
Collaborator:
Celgene Corporation
Information provided by:
Emory University
ClinicalTrials.gov Identifier:
NCT00209014
First received: September 13, 2005
Last updated: May 6, 2009
Last verified: May 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2006
  Estimated Primary Completion Date: No date given